Correspondence 0001104659-23-068754 from AYTU BIOPHARMA, INC (AYTU)

AYTU BIOPHARMA, INC
Date: June 7, 2023 · CIK: 0001385818 · Accession: 0001104659-23-068754

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-271556

Date

June 7, 2023

Author

Joshua R. Disbrow

Form

CORRESP

Company

AYTU BIOPHARMA, INC

Letter

Aytu Biopharma, Inc.

373 Inverness Parkway, Suite 206

Englewood, Colorado

June 7, 2023

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F. Street, N.E.

Washington, D.C. 20549

Attention: Jason L. Drory

Re: Aytu Biopharma, Inc. – Registration Statement on Form S-1 (File No. 333-271556)

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-1 (File No. 333-271556), as amended (the “Registration Statement”) of Aytu Biopharma, Inc. We respectfully request that the Registration Statement become effective as of 5:00 p.m., Eastern Time, on June 8, 2023, or as soon thereafter as is reasonably practicable. Once the Registration Statement has been declared effective, please confirm orally that event with our counsel, Dorsey & Whitney LLP, by calling Josh Erekson at (801) 933-4083.

Very truly yours,
Aytu Biopharma, Inc.

Show Raw Text

CORRESP
1
filename1.htm

Aytu Biopharma, Inc.

373 Inverness Parkway,
Suite 206

Englewood, Colorado
80112

June 7, 2023

VIA EDGAR

United States Securities
and Exchange Commission

Division of Corporation
Finance

100 F. Street, N.E.

Washington, D.C. 20549

Attention: Jason L. Drory

Re: Aytu Biopharma, Inc.
 – Registration Statement on Form S-1 (File No. 333-271556)

Ladies and Gentlemen:

In
accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the
Registration Statement on Form S-1 (File No. 333-271556), as amended (the “Registration Statement”) of Aytu Biopharma, Inc.
We respectfully request that the Registration Statement become effective as of 5:00 p.m., Eastern Time, on June 8, 2023, or as soon
thereafter as is reasonably practicable. Once the Registration Statement has been declared effective, please confirm orally that event
with our counsel, Dorsey & Whitney LLP, by calling Josh Erekson at (801) 933-4083.

    Very truly yours,

    Aytu Biopharma, Inc.

    By:
    /s/ Joshua R. Disbrow

    Name:
    Joshua R. Disbrow

    Title:
    Chief Executive Officer

SecProbe.io